secwatch.observer — SEC 8-K summary
======================================

Issuer:     Picard Medical, Inc. (PMI)
CIK:        0002030617
Form:       8-K
Filed at:   2026-07-02T12:15:19+00:00
Accession:  0001437749-26-022398
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Picard Medical reports 85% YoY revenue growth, gross margin improvement to 28% in pre-annual meeting presentation
--------------------------------------------------------------------------------

- Revenue increased 85% YoY; US revenue up 116%; gross margin improved to 28% from year-end 2025.
- Next-gen Emperor platform: pursuing FDA Breakthrough Device designation, IDE submission planned for 2028, clinical study in 2029.
- Annual meeting on July 17, 2026; proposals include director elections, capital structure amendments, auditor ratification, exec comp advisory vote.
- Interim CEO Richard Fang highlights business progress despite recent leadership changes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2030617/000143774926022398/0001437749-26-022398-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2030617/000143774926022398/pmi20251008_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-022398

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer